title: Establishment of opioid-induced rewarding effects under oxaliplatin- and Paclitaxel-induced neuropathy in rats.
abstract: The rewarding effects of μ-receptor agonists can be suppressed under several pain conditions. We recently showed that clinically used μ-receptor agonists possess efficacies for relieving the neuropathic pain induced by chemotherapeutic drug in rats; however, it is possible that the use of μ-receptor agonists may trigger the rewarding effects even under chemotherapeutic drug-induced neuropathic pain. Nevertheless, no information is available regarding whether μ-receptor agonists produce psychological dependence under chemotherapeutic drug-induced neuropathic pain. Therefore, we examined the effects of neuropathy induced by chemotherapeutic drugs on the rewarding effects of morphine, oxycodone, and fentanyl in rats. Repeated treatment with oxaliplatin or paclitaxel produced neuropathy as measured by the von Frey test. Rewarding effects produced by antinociceptive doses of μ-receptor agonists were not suppressed under oxaliplatin- or paclitaxel-induced neuropathy. Furthermore, the morphine-induced increase in the release of dopamine from the nucleus accumbens, which is a critical step in the rewarding effects of μ-receptor agonists, was not altered in paclitaxel-treated rats. These results suggest that the rewarding effects of μ-receptor agonists can still be established under oxaliplatin- or paclitaxel-induced neuropathic pain. Therefore, patients should be carefully monitored for psychological dependence on μ-receptor agonists when they are used to control chemotherapeutic drug-induced neuropathic pain.
authors.affiliation: Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Japan.
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Mori
authors.forename: Tomoe
authors.initials: T
authors.lastname: Kanbara
authors.forename: Masato
authors.initials: M
authors.lastname: Harumiya
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Iwase
authors.forename: Aki
authors.initials: A
authors.lastname: Masumoto
authors.forename: Sachiko
authors.initials: S
authors.lastname: Komiya
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakamura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shibasaki
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kanemasa
authors.forename: Gaku
authors.initials: G
authors.lastname: Sakaguchi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Suzuki
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D005283:Fentanyl / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D009020:Morphine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D009437:Neuralgia / Q000139:chemically induced* / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010098:Oxycodone / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D017239:Paclitaxel / Q000009:adverse effects*; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000819:agonists*; D019966:Substance-Related Disorders / Q000209:etiology
chemical_list: D000701:Analgesics, Opioid; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D017450:Receptors, Opioid, mu; D000077150:Oxaliplatin; D009020:Morphine; D010098:Oxycodone; D017239:Paclitaxel; D005283:Fentanyl